Completed PHASE1 INTERVENTIONAL 1-arm NCT02040064

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients (GEFTREM)

Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients

Sponsor: AstraZeneca

Conditions Non Small Cell Lung Cancer

Interventions Gefitinib Tremelimumab

Updated 5 times since 2017 Last updated: Jun 8, 2016 Started: Jan 31, 2014 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Non Small Cell Lung Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 5 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Villejuif, France